Figure 5.

Jurkat cells treated with integrin-activating agonists exhibit reduced surface CRT and ERp57. (A) WT or CRT^−/− cells were treated with combinations of doxorubicin and/or 9EG7 mAb and surface ERp57 determined by flow cytometry. (B,C) WT and CRT^−/− cells were treated with combinations of doxorubicin and MnCl₂ and surface CRT or surface ERp57 determined by flow. Flow gMFI plots are the mean ± S.D.; n = 3; p-values: *** < 0.001; ** < 0.01; ns, not significant. Data shown are representative of at least two independently conducted experiments.